Startups

Atalanta Therapeutics

Atalanta Therapeutics develops RNA interference medicines for diseases of the central nervous system. Its divalent small interfering RNA (di-siRNA) platform is designed to durably silence disease-associated genes across the brain and spinal cord, including deep brain regions. Its current published pipeline includes programs targeting HTT and MSH3 for Huntington’s disease, NAV1.7 for pain, and undisclosed CNS targets. These are investigational programs; its website places ATL-101 in IND-enabling development. The company also develops partnered programs with Genentech.

Founded 2018

Team

Adam SimpsonSenior Vice President, Head of Business Development

Anastasia KhvorovaScientific Co-Founder

Arno de WildeBoard Member

Bob BrownHead of Research & Development

Charlie AlbrightStrategic Advisor

Craig MelloScientific Co-Founder

Doug PagánBoard Member

Evan TzanisChief Development Officer

Jason P. HaflerBoard Member

Joanne KotzChief Executive Officer; Board Member

Neil AroninScientific Co-Founder

Niall O’DonnellBoard Member

Pedro Gonzalez-AlegreChief Medical Officer

Stacie WeningerBoard Member

Stephen KnightBoard Member

T. Scott JohnsonBoard Member

Investments

$97M2025-01-28	EQT Life Sciences, Sanofi Ventures, RiverVest Venture Partners, Novartis Venture Fund, Mirae Asset, F-Prime Capital, GHR Foundation, Pictet Alternative Advisors, abrdn Inc.
$—2021-01-11	F-Prime Capital

team@apexlogos.ai2 hours ago
Atalanta’s current own roster contains six leadership/advisory people and eight board members, with CEO Joanne Kotz appearing in both groups (13 unique current people). Three scientific co-founders are separately documented in its 2021 launch release, not inferred to have current executive positions. Doug Pagán is listed under Board of Directors as former CFO / COO; no current CFO role inferred. Current CEO and Bob Brown role use the latest roster rather than older 2025 announcement. Jason Hafler reuses JasonPHafler; T. Scott Johnson (Comanche physician) is distinct from ScottJohnson at Blitzscaling Ventures. The January2025 B had nine named investors: six recorded manager links and three pending full profiles (funds managed by abrdn Inc, Pictet Alternative Advisors, GHR Foundation). USD262m cumulative financing and partnerships and USD110m launch commitments are not individual equity round sizes. Current pipeline omits the KCNT1 program described in the 2025 financing release; company description follows current published pipeline without asserting a clinical trial started.